HeartBeam Inc. will host a conference call at 4:30 p.m. Eastern time on March 12, 2026, to discuss the company's financial results for the fourth quarter and full year ended Dec. 31, 2025, and provide updates on key strategic growth initiatives. These initiatives include the limited commercial launch and progress on its 12-lead ECG extended wear patch. A press release detailing the results will be issued prior to the call.
The company is dedicated to transforming the detection and monitoring of critical cardiac conditions. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The cleared indications for use for the HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment, which received FDA clearance in December 2025, can be referenced at https://www.heartbeam.com/indications for details on the intended use of its technology.
This announcement matters as it provides stakeholders with a scheduled opportunity to assess the company's financial health and the commercial progress of its innovative cardiac monitoring technology. The ability to conduct detailed cardiac assessments outside traditional medical settings has significant implications for patient access, early intervention, and potentially reducing healthcare costs associated with cardiac events. The conference call will offer insights into how the company is executing its strategy following recent regulatory milestones. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
